Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study

• Status: Recruiting
• Trial end date: 2020-07-25
• Target enrollment: 0
• Participant gender: All

Summary

At present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Max Healthcare Insititute Limited
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

1. Subjects within age group between 18 to 75 years

2. With either sex, male or female

3. Confirmed case of COVID-19 at Max Hospitals.

Exclusion Criteria:

• Patients who are critically sick